Search Result

Results for "

onset

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) AMPK (1) Apoptosis (9) Autophagy (9) Bacterial (3) CRAC Channel (1) Deubiquitinase (1) DNA/RNA Synthesis (4) Endogenous Metabolite (16) Factor Xa (1) Glucosidase (2) Histone Demethylase (4) Interleukin Related (1) Isotope-Labeled Compounds (3) Liposome (1) Melatonin Receptor (3) Parasite (2) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (9) Reactive Oxygen Species (1) ROCK (1) Serotonin Transporter (1) Sodium Channel (2) Thrombin (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (5) Endocrinology (13) Infection (4) Inflammation/Immunology (5) Metabolic Disease (9) Neurological Disease (23)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0546

Procaine 1 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine is a DNA-demethylating agent. Procaine acts through multiple targets and has a slow onset and a short duration of action .

HY-B0546A

Procaine hydrochloride 1 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-105077A

Nemifitide diTFA INN 00835 diTFA	5-HT Receptor	Neurological Disease
Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .

HY-145578

Linaprazan glurate X842	Others	Inflammation/Immunology
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .

HY-113202

Stearoylcarnitine 1 Publications Verification	Endogenous Metabolite	Neurological Disease Metabolic Disease
Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-111817

ACT-451840	Parasite	Infection
ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial .

HY-113202S

Stearoyl-L-carnitine-d3	Endogenous Metabolite	Neurological Disease Metabolic Disease
Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia[1].

HY-121307

Gliamilide	Others	Metabolic Disease
Gliamilide is an active and well tolerated sulfamylurea derivative and displays a very short plasma half-life. Gliamilide is promising for research of maturity-onset diabetic deseases .

HY-19905

GW-597901	Others	Others
GW-597901 is a compound with bronchodilator activity that has a stronger bronchodilator effect than salbutamol in a human lung reperfusion model, but with a slightly slower onset of action.

HY-113048

Erythronic acid	Endogenous Metabolite	Metabolic Disease
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-113048A

Erythronic acid potassium	Endogenous Metabolite	Metabolic Disease
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-B0481

Miglitol BAY1099; BAY-m1099	Glucosidase AMPK Reactive Oxygen Species	Metabolic Disease
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .

HY-B0546AS

Procaine-d4 hydrochloride	Histone Demethylase DNA/RNA Synthesis	Neurological Disease Cancer
Procaine-d₄ (hydrochloride) is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action[1][2].

HY-103214A

Bucindolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Bucindolol hydrochloride is a β-adrenergic receptor antagonist with activity in preventing new-onset atrial fibrillation. Bucindolol hydrochloride can reduce heart rate and the occurrence of bradycardia in patients with heart failure and atrial fibrillation .

HY-B0546AR

Procaine hydrochloride (Standard) 1 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine (hydrochloride) (Standard) is the analytical standard of Procaine (hydrochloride). This product is intended for research and analytical applications. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-136066

Tauro-ω-muricholic acid sodium TωMCA sodium	Others	Metabolic Disease
Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies

HY-10787

Ximelagatran 1 Publications Verification H 376/95	Thrombin	Cardiovascular Disease
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .

HY-101059

FGIN 1-27	Others	Neurological Disease
FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a K_i of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions .

HY-129451

HIE-124	Others	Others
HIE-124 is a potent ultra-short acting hypnotic that exhibits a rapid onset of action and a shorter duration of action with no acute tolerance or noticeable side effects. HIE-124 is promising for research of preanesthetic medication and anesthesia inducer .

HY-112528

Glycerophospho-N-palmitoyl ethanolamine GP-NPEA	Others	Metabolic Disease
Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .

HY-113909

Dinoprost (methoxyamine) Prostaglandin F2α (methoxyamine); PGF2α (methoxyamine)	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost methoxyamine is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost methoxyamine is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost methoxyamine plays a key role in the onset and progression of labour .

HY-12956

Dinoprost 2 Publications Verification Prostaglandin F2α; PGF2α	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-Y0378

D-Leucine (R)-Leucine	Endogenous Metabolite	Neurological Disease
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-P99491

Camoteskimab 1 Publications Verification AVTX-007; CERC-007; MEDI 2338	Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-12956A

Dinoprost tromethamine salt 2 Publications Verification Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .

HY-12956S1

Dinoprost-d9 Prostaglandin F2a-d₉; PGF2α-d₉	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost-d₉ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour[1][2].

HY-12956S

Dinoprost-d4 Prostaglandin F2a-d₄; PGF2α-d₄	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost-d₄ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour[1][2].

HY-110216

5J-4	CRAC Channel	Inflammation/Immunology
5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation .

HY-106018A

Mitemcinal fumarate GM 611 fumarate	Others	Others
Mitemcinal fumarate is an oral motilium agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal fumarate may be a constipation suppressant due to its early onset and short duration of action.

HY-A0014

Ramelteon Maximum Cited Publications 7 Publications Verification TAK-375	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-143656

SH379	Autophagy	Endocrinology
SH379 is the derivative of 2-methylpyrimidine-fused tricyclic diterpene. SH379 is a potent and orally active anti-late-onset hypogonadism agent. SH379 significantly promotes the expression of the key testosterone synthesis-related enzymes StAR and 3β-HSD. SH379 stimulates autophagy through regulating AMPK/mTOR signaling pathway .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-113246

15-keto-Prostaglandin F2a 15-keto-PGF2α	Prostaglandin Receptor Endogenous Metabolite	Endocrinology
15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. Prostaglandin F2α. Prostaglandin F2α is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist and plays a key role in the onset and progression of labour .

HY-12956R

Dinoprost (Standard)	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost (Standard) is the analytical standard of Dinoprost. This product is intended for research and analytical applications. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-106018

Mitemcinal GM 611	Others	Others
Mitemcinal (GM 611) is an oral motilium agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal may be a constipation suppressant due to its early onset and short duration of action. .

HY-14905

Uridine triacetate Tri-O-acetyl uridine	Others	Neurological Disease
Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-12956S2

Dinoprost-13C5 Prostaglandin F2α-¹³C5; PGF2α-¹³C₅	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis Isotope-Labeled Compounds	Endocrinology
Dinoprost- ¹³C₅ is ¹³C labeled Dinoprost (HY-12956). Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-Y0378R

D-Leucine (Standard)	Endogenous Metabolite	Neurological Disease
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-12956AR

Dinoprost tromethamine salt (Standard)	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost (tromethamine salt) (Standard) is the analytical standard of Dinoprost (tromethamine salt). This product is intended for research and analytical applications. Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-A0014S

Ramelteon-d5 TAK-375-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA	Liposome	Neurological Disease
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

HY-119035

R-75317	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .

HY-A0014R

Ramelteon (Standard)	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon (Standard) is the analytical standard of Ramelteon. This product is intended for research and analytical applications. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-123429

CK0683A	Others	Infection
CK0683A is a novel biaminourea antibiotic with antiplaque effects and demonstrated efficacy in experimental mouse dental disease models. A 12-week study in beagles compared its efficacy in terms of plaque and gingivitis reduction, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease is similar to that of humans. As a positive control for plaque and gingivitis reduction and staining, chlorhexidine acetate was selected because it is effective in both humans and dogs.

HY-P99803

Clervonafusp alfa VAL-1221	Glucosidase	Others
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .

HY-123479

CK0492B	Others	Infection
CK0492B is a novel biaminourea antibiotic that has antiplaque properties in vitro and has shown efficacy in an experimental mouse dental disease model. A 12-week study in beagles compared its efficacy in reducing plaque and gingivitis, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease are similar to humans. Chlorhexidine acetate was selected as a positive control for plaque and gingivitis reduction and staining because it is effective in both humans and dogs.

HY-136528

RA-9	Deubiquitinase Apoptosis	Cancer
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,644 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,644 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L040

Anti-diabetic Compound Library

776 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 776 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-105077A

Nemifitide diTFA INN 00835 diTFA	5-HT Receptor	Neurological Disease
Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .

HY-P2378

Neuromedin U-25 (human)	Peptides	Cardiovascular Disease
Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .

HY-P5451

PLP (178-191)	Peptides	Others
PLP (178-191) is a biological active peptide. (This is amino acids 178 to 191 fragment of the proteolipid protein (PLP), an immunodominant encephalitogenic epitope in SJL mice, one of two major encephalitogenic epitopes. PLP peptide 178 to 191 was compared with another encephalitogenic peptide, 139 to 151. The day of onset of disease induced by PLP 178 to 191 was earlier, but the incidence, severity, and histologic features were indistinguishable.)

Cat. No.	Product Name	Target	Research Area

HY-P99491

Camoteskimab 1 Publications Verification AVTX-007; CERC-007; MEDI 2338	Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .

HY-108786

Asfotase alfa ENB-0040	Inhibitory Antibodies	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^?/? knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

HY-P99803

Clervonafusp alfa VAL-1221	Glucosidase	Others
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113202

Stearoylcarnitine 1 Publications Verification	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-113048A

Erythronic acid potassium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Endogenous Metabolite
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-12956

Dinoprost 2 Publications Verification Prostaglandin F2α; PGF2α	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-Y0378

D-Leucine (R)-Leucine	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-12956A

Dinoprost tromethamine salt 2 Publications Verification Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-113246

15-keto-Prostaglandin F2a 15-keto-PGF2α	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Prostaglandin Receptor Endogenous Metabolite
15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. Prostaglandin F2α. Prostaglandin F2α is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist and plays a key role in the onset and progression of labour .

HY-113048

Erythronic acid	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Endogenous Metabolite
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-12956R

Dinoprost (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (Standard) is the analytical standard of Dinoprost. This product is intended for research and analytical applications. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-Y0378R

D-Leucine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-12956AR

Dinoprost tromethamine salt (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (tromethamine salt) (Standard) is the analytical standard of Dinoprost (tromethamine salt). This product is intended for research and analytical applications. Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

Cat. No.	Product Name	Chemical Structure

HY-12956S

Dinoprost-d4
Dinoprost-d₄ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour[1][2].

HY-Y0378S

D-Leucine-d10
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-113202S

Stearoyl-L-carnitine-d3
Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia[1].

HY-B0546AS

Procaine-d4 hydrochloride
Procaine-d₄ (hydrochloride) is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action[1][2].

HY-12956S1

Dinoprost-d9
Dinoprost-d₉ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour[1][2].

HY-12956S2

Dinoprost-13C5
Dinoprost- ¹³C₅ is ¹³C labeled Dinoprost (HY-12956). Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-A0014S

Ramelteon-d5

Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

Cat. No.	Product Name		Classification

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA		Phospholipids
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

onset

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products